Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	B-cell_type
by	O
1	O
,	O
25-dihydroxycholecalciferol	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
demonstrate	O
that	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10	O
,	O
000-fold	O
in	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
and	O
unfractionated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O

Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
intracellular	I-protein
receptor	I-protein
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O

These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

88	NULL
,	NULL
gp	NULL
.	NULL

6632-6636	NULL
,	NULL
August	NULL
1991	NULL
Medical	NULL
Sciences	NULL
Enhancement	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
replication	NULL
in	NULL
monocytes	NULL
by	NULL
1,25-dihydroxycholecalciferol	NULL
(	NULL
AIDS/vitamin	NULL
D/calcitriol	NULL
)	NULL
Paur	NULL
R	NULL
.	NULL

Skorni	NULL
«	NULL
*	NULL
?	NULL

,	NULL
BEATRICE	NULL
Jannt	NULL
,	NULL
Monica	NULL
Z.	NULL
Wang*	NULL
,	NULL
TERESA	NULL
R	NULL
.	NULL

Rota	NULL
$	NULL
!	NULL

,	NULL
Martin	NULL
S.	NULL
AND	NULL
STEPHEN	NULL
M.	NULL
Kranet	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Tufts	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
and	NULL
Division	NULL
of	NULL
Geographic	NULL
Medicine	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
New	NULL
England	NULL
Medical	NULL
Center	NULL
Hospitals	NULL
,	NULL
750	NULL
Washington	NULL
Street	NULL
,	NULL
NEMCH	NULL
67	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02111	NULL
;	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
*Arthritis	NULL
Unit	NULL
and	NULL
#	NULL
Infectious	NULL
Disease	NULL
Unit	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
Fruit	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02114	NULL
Communicated	NULL
by	NULL
Bernard	NULL
N.	NULL
Fields	NULL
,	NULL
April	NULL
8	NULL
,	NULL
1991	NULL
ABSTRACT	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
expression	NULL
and	NULL
replication	NULL
are	NULL
under	NULL
tight	NULL
regulatory	NULL
control	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
1,25-dihydroxycholecalciferol	NULL
{	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
]	NULL
enhances	NULL
the	NULL
replication	NULL
of	NULL
monocyte-	NULL
and	NULL
lympho-cyte-tropic	NULL
strains	NULL
of	NULL
HIV-1	NULL
up	NULL
to	NULL
10,000-fold	NULL
in	NULL
monocyte	NULL
cell	NULL
lines	NULL
,	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
,	NULL
and	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
therefore	NULL
one	NULL
of	NULL
the	NULL
most	NULL
potent	NULL
regulators	NULL
of	NULL
HIV-1	NULL
replication	NULL
described	NULL
to	NULL
date	NULL
.	NULL

Precursors	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
in	NULL
proportion	NULL
to	NULL
their	NULL
affinity	NULL
for	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
intracellular	NULL
receptor	NULL
,	NULL
suggesting	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
influences	NULL
HIV-1	NULL
replication	NULL
by	NULL
mechanisms	NULL
involving	NULL
this	NULL
receptor	NULL
.	NULL

These	NULL
studies	NULL
may	NULL
have	NULL
important	NULL
implications	NULL
for	NULL
the	NULL
design	NULL
of	NULL
effective	NULL
therapy	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

The	NULL
monocyte	NULL
is	NULL
thought	NULL
to	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
patho-genesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-related	NULL
illness	NULL
(	NULL
1	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
active	NULL
viral	NULL
replication	NULL
in	NULL
mono-cyte/macrophages	NULL
may	NULL
lead	NULL
to	NULL
tissue	NULL
injury	NULL
,	NULL
transmission	NULL
of	NULL
virus	NULL
to	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
passage	NULL
of	NULL
virus	NULL
between	NULL
various	NULL
organ	NULL
systems	NULL
within	NULL
the	NULL
body	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
across	NULL
the	NULL
blood-brain	NULL
or	NULL
blood-retina	NULL
barrier	NULL
)	NULL
,	NULL
and	NULL
eventual	NULL
progression	NULL
to	NULL
HIV-related	NULL
illness	NULL
.	NULL

Understanding	NULL
the	NULL
factors	NULL
that	NULL
regulate	NULL
HIV-1	NULL
replication	NULL
in	NULL
monocytes	NULL
could	NULL
lead	NULL
to	NULL
new	NULL
approaches	NULL
capable	NULL
of	NULL
modulating	NULL
disease	NULL
expression	NULL
in	NULL
those	NULL
tissues	NULL
harboring	NULL
HIV-1-infected	NULL
monocyte/macrophages	NULL
.	NULL

Expression	NULL
of	NULL
HIV	NULL
in	NULL
monocytes	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
several	NULL
cell	NULL
regulatory	NULL
factors	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

1,25-Dihydroxycholecalciferol	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
]	NULL
,	NULL
the	NULL
biologically	NULL
active	NULL
form	NULL
of	NULL
vitamin	NULL
D	NULL
,	NULL
has	NULL
multiple	NULL
effects	NULL
on	NULL
cellular	NULL
differentiation	NULL
and	NULL
function	NULL
,	NULL
including	NULL
regulation	NULL
of	NULL
surface	NULL
differentiation	NULL
anti-gens	NULL
,	NULL
oncogene	NULL
expression	NULL
,	NULL
cytokine	NULL
production	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
activity	NULL
,	NULL
phagocytosis	NULL
,	NULL
and	NULL
heat-shock	NULL
protein	NULL
production	NULL
(	NULL
reviewed	NULL
in	NULL
refs	NULL
.	NULL

4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
HIV-1	NULL
replication	NULL
is	NULL
related	NULL
to	NULL
the	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
antigen	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
and	NULL
the	NULL
state	NULL
of	NULL
activation	NULL
of	NULL
cells	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
might	NULL
affect	NULL
HIV-1	NULL
replication	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
evaluated	NULL
HIV-1	NULL
replication	NULL
in	NULL
a	NULL
monocytoid	NULL
cell	NULL
line	NULL
,	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
,	NULL
and	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

HIV-1	NULL
replication	NULL
was	NULL
enhanced	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
all	NULL
of	NULL
these	NULL
cells	NULL
at	NULL
physiologic	NULL
and	NULL
supra-physiologic	NULL
concentrations	NULL
.	NULL

This	NULL
enhancement	NULL
involves	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
intracellular	NULL
receptor	NULL
;	NULL
precursors	NULL
and	NULL
analogs	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
in	NULL
proportion	NULL
to	NULL
their	NULL
affinity	NULL
for	NULL
this	NULL
receptor	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

6632	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Lines	NULL
and	NULL
Virus	NULL
Stocks	NULL
.	NULL

BT4A3.5	NULL
(	NULL
A3.5	NULL
)	NULL
cells	NULL
are	NULL
a	NULL
clone	NULL
of	NULL
monocytic	NULL
cells	NULL
that	NULL
were	NULL
isolated	NULL
from	NULL
human	NULL
bone	NULL
cell	NULL
cultures	NULL
(	NULL
these	NULL
cells	NULL
were	NULL
originally	NULL
isolated	NULL
and	NULL
characterized	NULL
by	NULL
S.	NULL
R.	NULL
Goldring	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
B.	NULL
Jahn	NULL
,	NULL
A.	NULL
Duran	NULL
,	NULL
and	NULL
S.M.K	NULL
.	NULL

,	NULL
unpublished	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
are	NULL
CD4*	NULL
,	NULL
HLA-DR	NULL
*	NULL
,	NULL
CD15*	NULL
(	NULL
Leu-M1*	NULL
)	NULL
,	NULL
and	NULL
CD3~	NULL
,	NULL
they	NULL
produce	NULL
interleukin	NULL
1	NULL
after	NULL
stimulation	NULL
with	NULL
endotoxin	NULL
,	NULL
and	NULL
they	NULL
are	NULL
susceptible	NULL
to	NULL
infection	NULL
with	NULL
lymphocyte-	NULL
and	NULL
monocyte-tropic	NULL
strains	NULL
of	NULL
HIV-1	NULL
.	NULL

Peripheral	NULL
blood	NULL
monocytes	NULL
were	NULL
separated	NULL
from	NULL
PBMC	NULL
of	NULL
HIV-1	NULL
seronegative	NULL
donors	NULL
by	NULL
counterflow	NULL
cen-trifugation	NULL
(	NULL
elutriation	NULL
)	NULL
in	NULL
a	NULL
Beckman	NULL
JE-5.0	NULL
elutriator	NULL
chamber	NULL
and	NULL
rotor	NULL
.	NULL

This	NULL
method	NULL
allows	NULL
for	NULL
the	NULL
separation	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
minimally	NULL
activated	NULL
,	NULL
highly	NULL
purified	NULL
monocytes	NULL
(	NULL
10	NULL
)	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

HIV-lims	NULL
and	NULL
H9	NULL
cells	NULL
were	NULL
a	NULL
gift	NULL
of	NULL
R.	NULL
Gallo	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
)	NULL
.	NULL

U1	NULL
cells	NULL
and	NULL
HIV-1§..1	NULL
were	NULL
provided	NULL
by	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
AIDS	NULL
Reagent	NULL
Program	NULL
.	NULL

All	NULL
cells	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
(	NULL
except	NULL
U1	NULL
cells	NULL
)	NULL
were	NULL
tested	NULL
and	NULL
found	NULL
to	NULL
be	NULL
free	NULL
of	NULL
mycoplasma	NULL
contamination	NULL
.	NULL

Cultures	NULL
of	NULL
A3.5	NULL
Cells	NULL
.	NULL

A3.5	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV-1ing	NULL
{	NULL
multiplicity	NULL
of	NULL
infection	NULL
(	NULL
moi	NULL
)	NULL
=	NULL
1	NULL
x	NULL
107	NULL
tissue	NULL
culture	NULL
infectious	NULL
doses	NULL
,	NULL
(	NULL
TCIDs	NULL
,	NULL
)	NULL
per	NULL
celll	NULL
and	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
GIBCO	NULL
or	NULL
Sigma	NULL
)	NULL
.	NULL

TCID	NULL
;	NULL
,	NULL
was	NULL
determined	NULL
by	NULL
serial	NULL
dilution	NULL
of	NULL
viral	NULL
stock	NULL
supernatant	NULL
fluid	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
syncytium	NULL
formation	NULL
by	NULL
C8166	NULL
cells	NULL
as	NULL
described	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Every	NULL
3-4	NULL
days	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
sampled	NULL
for	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
by	NULL
ELISA	NULL
(	NULL
DuPont/NEN	NULL
)	NULL
.	NULL

Supernatant	NULL
fluids	NULL
and	NULL
cells	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
syncytium	NULL
formation	NULL
in	NULL
C€8166	NULL
cells	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

At	NULL
selected	NULL
times	NULL
,	NULL
cells	NULL
from	NULL
the	NULL
cultures	NULL
were	NULL
stained	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
,	NULL
after	NULL
blocking	NULL
Fc	NULL
receptors	NULL
with	NULL
heat-aggregated	NULL
immunoglobulins	NULL
,	NULL
using	NULL
a	NULL
polyclonal	NULL
antiserum	NULL
against	NULL
HIV-1	NULL
and	NULL
a	NULL
fluorescein	NULL
isothi0o-cyanate-conjugated	NULL
sheep	NULL
antibody	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragment	NULL
to	NULL
human	NULL
immunoglobulin	NULL
(	NULL
Organon	NULL
Teknika-Cappel	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
counting	NULL
at	NULL
least	NULL
300	NULL
cells	NULL
using	NULL
a	NULL
Zeiss	NULL
Axioskop	NULL
MC100	NULL
microscope	NULL
.	NULL

Abbreviations	NULL
:	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
;	NULL
moi	NULL
,	NULL
multiplicity	NULL
of	NULL
infection	NULL
;	NULL
TCIDs	NULL
,	NULL
,	NULL
tissue	NULL
culture	NULL
infectious	NULL
doses	NULL
;	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
1,25-dihydroxy-	NULL
cholecalciferol	NULL
;	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
,	NULL
25-hydroxycholecalciferol	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Present	NULL
address	NULL
:	NULL
Laboratorio	NULL
de	NULL
Referencia	NULL
de	NULL
HIV	NULL
,	NULL
Instituto	NULL
de	NULL
Higiéne	NULL
Rafael	NULL
Rangel	NULL
,	NULL
Cuidad	NULL
Universitaria	NULL
,	NULL
Apartado	NULL
del	NULL
Este	NULL
60412	NULL
,	NULL
Caracas	NULL
,	NULL
Venezuela	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Skolnik	NULL
et	NULL
al	NULL
.	NULL

Cultures	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
Precursors	NULL
.	NULL

A3.5	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
24	NULL
hr	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
infected	NULL
with	NULL
HIV-ljs	NULL
(	NULL
moi	NULL
=	NULL
1	NULL
x	NULL
10~	NULL
>	NULL
TCIDs	NULL
,	NULL
per	NULL
cell	NULL
)	NULL
,	NULL
and	NULL
then	NULL
cultured	NULL
with	NULL
the	NULL
appropriate	NULL
concentration	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Every	NULL
3-4	NULL
days	NULL
,	NULL
supernatant	NULL
fluids	NULL
were	NULL
assayed	NULL
for	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
by	NULL
ELISA	NULL
(	NULL
DuPont/NEN	NULL
)	NULL
and	NULL
,	NULL
on	NULL
selected	NULL
days	NULL
,	NULL
were	NULL
assayed	NULL
for	NULL
HIV-1	NULL
virus	NULL
yield	NULL
[	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
11	NULL
)	NULL
]	NULL
.	NULL

An	NULL
aliquot	NULL
from	NULL
each	NULL
sample	NULL
was	NULL
assayed	NULL
for	NULL
cell	NULL
viability	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Fresh	NULL
medium	NULL
was	NULL
added	NULL
every	NULL
3-4	NULL
days	NULL
with	NULL
the	NULL
appropriate	NULL
concentration	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

For	NULL
the	NULL
experiment	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
and	NULL
others	NULL
(	NULL
including	NULL
those	NULL
with	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
)	NULL
,	NULL
HIV-1	NULL
(	NULL
moi	NULL
=	NULL
5	NULL
x	NULL
10~	NULL
>	NULL
TCIDs	NULL
,	NULL
per	NULL
cell	NULL
)	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
added	NULL
simultaneously	NULL
to	NULL
the	NULL
cells	NULL
.	NULL

Cocultures	NULL
of	NULL
PBMC	NULL
.	NULL

PBMC	NULL
were	NULL
isolated	NULL
from	NULL
HIV-1	NULL
seropositive	NULL
individuals	NULL
by	NULL
Ficoll/Hypaque	NULL
density	NULL
centrif-ugation	NULL
of	NULL
heparinized	NULL
peripheral	NULL
blood	NULL
(	NULL
<	NULL
10	NULL
units/ml	NULL
)	NULL
.	NULL

Cocultures	NULL
were	NULL
performed	NULL
with	NULL
PBMC	NULL
from	NULL
HIV-1	NULL
seronegative	NULL
donors	NULL
prestimulated	NULL
for	NULL
3-4	NULL
days	NULL
with	NULL
phytohemagglu-tinin	NULL
P	NULL
(	NULL
Difco	NULL
)	NULL
and	NULL
interleukin	NULL
2	NULL
(	NULL
Pharmacia	NULL
)	NULL
as	NULL
described	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Four	NULL
parallel	NULL
cocultures	NULL
were	NULL
performed	NULL
:	NULL
these	NULL
cocultures	NULL
contained	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
24	NULL
nM	NULL
)	NULL
,	NULL
Polybrene	NULL
(	NULL
2	NULL
ug/ml	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
Polybrene	NULL
(	NULL
24	NULL
nM	NULL
and	NULL
2	NULL
ug/ml	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
or	NULL
no	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
Polybrene	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
and	NULL
Precursors	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
M.	NULL
R.	NULL
Uskokovi¢	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
)	NULL
.	NULL

Cholecalciferol	NULL
and	NULL
7-dehydrocholesterol	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

25-Hydroxycholecalciferol	NULL
[	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
]	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
M.	NULL
F.	NULL
Hol-ick	NULL
(	NULL
Boston	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Surface	NULL
Marker	NULL
Expression	NULL
Determination	NULL
.	NULL

A3.5	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
45	NULL
min	NULL
with	NULL
heat-aggregated	NULL
immunoglobulins	NULL
to	NULL
block	NULL
Fc	NULL
receptors	NULL
and	NULL
then	NULL
stained	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
with	NULL
the	NULL
relevant	NULL
monoclonal	NULL
antibody	NULL
and	NULL
fluorescein-conjugated	NULL
goat	NULL
anti-mouse	NULL
conjugate	NULL
(	NULL
13	NULL
)	NULL
.	NULL

After	NULL
fixation	NULL
with	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
,	NULL
at	NULL
least	NULL
2000	NULL
cells	NULL
per	NULL
sample	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

RESULTS	NULL
The	NULL
time	NULL
course	NULL
of	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
and	NULL
cell	NULL
viability	NULL
after	NULL
infection	NULL
of	NULL
A3.5	NULL
cells	NULL
with	NULL
HIV-lims	NULL
(	NULL
a	NULL
lym-phocyte-tropic	NULL
strain	NULL
of	NULL
HIV-1	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

No	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
was	NULL
detectable	NULL
for	NULL
the	NULL
first	NULL
21	NULL
days	NULL
of	NULL
culture	NULL
after	NULL
acute	NULL
infection	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Syncytium	NULL
formation	NULL
with	NULL
C8166	NULL
cells	NULL
oc-	NULL
A	NULL
>	NULL
3000	NULL
}	NULL
7100	NULL
~	NULL
pS	NULL
R	NULL
a	NULL
(	NULL
3	NULL
19g	NULL
~	NULL
$	NULL
2x00	NULL
}	NULL
e	NULL
C-	NULL
far	NULL
]	NULL
a	NULL
L	NULL
ty	NULL
§	NULL
(	NULL
n	NULL
$	NULL
R	NULL
1000	NULL
&	NULL
m	NULL
&	NULL
x	NULL
-	NULL
7	NULL
~	NULL
&	NULL
L	NULL
T	NULL
10	NULL
a	NULL
Lo	NULL
ica	NULL
cL	NULL
4	NULL
Luol	NULL
ug	NULL
i	NULL
i	NULL
1	NULL
J	NULL
Days	NULL
0	NULL
:	NULL
3034384450	NULL
-	NULL
6569	NULL
77	NULL
&	NULL
-	NULL
100	NULL
127	NULL
B	NULL
IF	NULL
(	NULL
%	NULL
pos	NULL
)	NULL
-	NULL
o	NULL
26	NULL
60	NULL
36	NULL
19	NULL
2040	NULL
31	NULL
17	NULL
40	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
,	NULL
cell	NULL
viability	NULL
,	NULL
and	NULL
HIV-1	NULL
antigen	NULL
expression	NULL
after	NULL
infection	NULL
of	NULL
A3.5	NULL
cells	NULL
with	NULL
(	NULL
4	NULL
)	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
and	NULL
percentage	NULL
of	NULL
viable	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
IF	NULL
,	NULL
percentage	NULL
of	NULL
cells	NULL
staining	NULL
with	NULL
anti-HIV-1	NULL
antibody	NULL
(	NULL
%	NULL
pos	NULL
.	NULL
)	NULL

by	NULL
indirect	NULL
immunofluorescence	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
6633	NULL
curred	NULL
7	NULL
days	NULL
after	NULL
infection	NULL
.	NULL

Chronic	NULL
infection	NULL
ensued	NULL
with	NULL
17-60	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
expressing	NULL
HIV-1	NULL
antigens	NULL
at	NULL
any	NULL
given	NULL
time	NULL
.	NULL

We	NULL
thus	NULL
know	NULL
that	NULL
this	NULL
cell	NULL
line	NULL
is	NULL
susceptible	NULL
to	NULL
infection	NULL
with	NULL
HIV-1ms	NULL
and	NULL
can	NULL
be	NULL
maintained	NULL
continuously	NULL
in	NULL
culture	NULL
with	NULL
ongoing	NULL
HIV-1	NULL
replication	NULL
.	NULL

The	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
its	NULL
precursors	NULL
in	NULL
the	NULL
present	NULL
investigations	NULL
all	NULL
utilized	NULL
acutely	NULL
infected	NULL
A3.5	NULL
cells	NULL
.	NULL

A3.5	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
24	NULL
hr	NULL
and	NULL
then	NULL
infected	NULL
with	NULL
HIV-1	NULL
igs	NULL
(	NULL
moi	NULL
=	NULL
1.0	NULL
x	NULL
107	NULL
TCIDs	NULL
,	NULL
per	NULL
cell	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
and	NULL
B	NULL
,	NULL
HIV-1	NULL
replication	NULL
was	NULL
enhanced	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Enhancement	NULL
was	NULL
between	NULL
1000-	NULL
and	NULL
10,000-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
24	NULL
nM	NULL
or	NULL
240	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
after	NULL
10-14	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

Virus	NULL
yield	NULL
assays	NULL
confirmed	NULL
this	NULL
augmentation	NULL
;	NULL
for	NULL
example	NULL
,	NULL
virus	NULL
titers	NULL
(	NULL
TCIDs	NULL
,	NULL
per	NULL
ml	NULL
)	NULL
after	NULL
10	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
experiment	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
were	NULL
2.1	NULL
x	NULL
10°	NULL
,	NULL
1.5	NULL
x	NULL
104	NULL
,	NULL
1.0	NULL
x	NULL
10°	NULL
,	NULL
and	NULL
1.0	NULL
x	NULL
10	NULL
``	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0	NULL
M	NULL
,	NULL
2.4	NULL
nM	NULL
,	NULL
24	NULL
nM	NULL
,	NULL
and	NULL
240	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
replicated	NULL
nine	NULL
times	NULL
with	NULL
changes	NULL
in	NULL
the	NULL
protocol	NULL
that	NULL
included	NULL
various	NULL
moi	NULL
of	NULL
HIV-1ims	NULL
(	NULL
6	NULL
x	NULL
107+	NULL
,	NULL
1	NULL
x	NULL
107	NULL
``	NULL
,	NULL
and	NULL
5	NULL
x	NULL
10-5	NULL
)	NULL
,	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
from	NULL
12	NULL
pM	NULL
to	NULL
240	NULL
nM	NULL
,	NULL
and	NULL
either	NULL
pretreatment	NULL
of	NULL
cells	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
or	NULL
simultaneous	NULL
addition	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
HIV-1	NULL
.	NULL

Enhancement	NULL
was	NULL
seen	NULL
with	NULL
every	NULL
protocol	NULL
at	NULL
every	NULL
concentration	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
tested	NULL
from	NULL
7-10	NULL
days	NULL
after	NULL
infection	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
HIV-ligg	NULL
.	NULL

Enhancement	NULL
was	NULL
2-	NULL
to	NULL
3-fold	NULL
at	NULL
12-60	NULL
pM	NULL
E	NULL
EA	NULL
|	NULL
.	NULL

[	NULL
wo	NULL
(	NULL
30	NULL
)	NULL
10°F	NULL
arya	NULL
146	NULL
)	NULL
/	NULL
E	NULL
(	NULL
)	NULL
%	NULL
Viability	NULL
y	NULL
F591	NULL
I	NULL
|	NULL
10	NULL
%	NULL
,	NULL
A	NULL
,	NULL
{	NULL
102	NULL
10	NULL
}	NULL
xp	NULL
HIV-1	NULL
p24	NULL
ANTIGEN	NULL
(	NULL
ng/1x	NULL
10	NULL
%	NULL
celts	NULL
)	NULL
``	NULL
o	NULL
_-	NULL
002	NULL
0.24	NULL
to	NULL
10°	NULL
Torry	NULL
10°	NULL
Torry	NULL
coccal	NULL
pop	NULL
ucla	NULL
inl	NULL
a	NULL
a	NULL
aad	NULL
al	NULL
19°	NULL
10°	NULL
10°	NULL
HIV-L	NULL
p24	NULL
ANTIGEN	NULL
(	NULL
ng/1x	NULL
10	NULL
%	NULL
celts	NULL
/	NULL
10	NULL
``	NULL
/M	NULL
)	NULL
1	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D3	NULL
CONCENTRATION	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
and	NULL
cell	NULL
viability	NULL
in	NULL
A3.5	NULL
cells	NULL
pretreated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
infected	NULL
with	NULL
HIV-lims	NULL
that	NULL
were	NULL
assayed	NULL
on	NULL
days	NULL
10	NULL
and	NULL
14	NULL
after	NULL
infection	NULL
(	NULL
note	NULL
logarithmic	NULL
scales	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Induction	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
A3.5	NULL
cells	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
the	NULL
time	NULL
of	NULL
infection	NULL
with	NULL
HIV-1j18	NULL
and	NULL
assayed	NULL
after	NULL
7	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

The	NULL
Pearson	NULL
correlation	NULL
coef-	NULL
ficient	NULL
for	NULL
B	NULL
is	NULL
0.88	NULL
.	NULL

6634	NULL
Medical	NULL
Sciences	NULL
:	NULL
Skolnik	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
Table	NULL
1	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhances	NULL
HIV-1	NULL
replication	NULL
in	NULL
U937	NULL
and	NULL
A3.5	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
U1	NULL
cells	NULL
Day	NULL
7	NULL
Day	NULL
10	NULL
Day	NULL
14	NULL
Cell	NULL
type	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
nM	NULL
HIV-1	NULL
p24	NULL
%	NULL
viable	NULL
HIV-1	NULL
p24	NULL
%	NULL
viable	NULL
HIV-1	NULL
p24	NULL
%	NULL
viable	NULL
A3.5	NULL
0	NULL
0.10	NULL
98	NULL
0.30	NULL
95	NULL
0.74	NULL
94	NULL
24	NULL
14.5	NULL
76	NULL
492.0	NULL
87	NULL
6533.0	NULL
43	NULL
U937	NULL
0	NULL
0.37	NULL
94	NULL
7.5	NULL
91	NULL
ND	NULL
ND	NULL
24	NULL
33.0	NULL
97	NULL
1107.0	NULL
76	NULL
ND	NULL
ND	NULL
U1	NULL
0	NULL
0.13	NULL
86	NULL
0.16	NULL
93	NULL
0.10	NULL
95	NULL
24	NULL
0.07	NULL
93	NULL
0.18	NULL
%	NULL
0.12	NULL
98	NULL
A3.5	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
moi	NULL
=	NULL
1	NULL
x	NULL
10~	NULL
>	NULL
)	NULL
and	NULL
treated	NULL
at	NULL
the	NULL
start	NULL
of	NULL
the	NULL
experiment	NULL
and	NULL
thereafter	NULL
with	NULL
24	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

U1	NULL
cells	NULL
(	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
only	NULL
24	NULL
nM	NULL
is	NULL
depicted	NULL
)	NULL
without	NULL
additional	NULL
virus	NULL
input	NULL
.	NULL

HIV	NULL
p24	NULL
antigen	NULL
production	NULL
is	NULL
expressed	NULL
as	NULL
ng	NULL
per	NULL
10°	NULL
cells	NULL
.	NULL

Cell	NULL
viability	NULL
is	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
viable	NULL
cells	NULL
(	NULL
%	NULL
viable	NULL
)	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

and	NULL
2.5-	NULL
to	NULL
10-fold	NULL
at	NULL
0.12	NULL
nM	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
normally	NULL
present	NULL
in	NULL
plasma	NULL
at	NULL
concentrations	NULL
of	NULL
~0.12	NULL
nM	NULL
;	NULL
therefore	NULL
,	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
occurs	NULL
at	NULL
physiologic	NULL
concentrations	NULL
.	NULL

One-hundred-	NULL
to	NULL
10,000-fold	NULL
enhancement	NULL
was	NULL
always	NULL
demonstrated	NULL
after	NULL
10-14	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
24	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

This	NULL
may	NULL
be	NULL
important	NULL
since	NULL
local	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
vivo	NULL
may	NULL
exceed	NULL
circulating	NULL
plasma	NULL
levels	NULL
.	NULL

No	NULL
effect	NULL
on	NULL
HIV-1	NULL
replication	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
95	NULL
%	NULL
ethanol	NULL
used	NULL
to	NULL
dissolve	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:2000	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
HIV-1	NULL
replication	NULL
were	NULL
not	NULL
limited	NULL
to	NULL
the	NULL
A3.5	NULL
monocyte	NULL
line	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
another	NULL
monocytoid	NULL
line	NULL
)	NULL
exceeded	NULL
that	NULL
in	NULL
A3.5	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
HIV-1	NULL
replication	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
the	NULL
U1	NULL
clone	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

The	NULL
U1	NULL
clone	NULL
is	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
,	NULL
and	NULL
HIV-1	NULL
replication	NULL
can	NULL
be	NULL
modulated	NULL
by	NULL
several	NULL
cytokines	NULL
and	NULL
other	NULL
activating	NULL
agents	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
was	NULL
also	NULL
not	NULL
observed	NULL
in	NULL
the	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
H9	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
HIV-1	NULL
replication	NULL
may	NULL
be	NULL
largely	NULL
limited	NULL
to	NULL
monocytic	NULL
cells	NULL
.	NULL

Since	NULL
monocytoid	NULL
lines	NULL
may	NULL
differ	NULL
from	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
in	NULL
their	NULL
response	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
the	NULL
replication	NULL
of	NULL
a	NULL
monocyte-tropic	NULL
strain	NULL
of	NULL
HIV-1	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
.	NULL

Monocytes	NULL
were	NULL
separated	NULL
from	NULL
blood	NULL
of	NULL
HIV-1	NULL
seronegative	NULL
donors	NULL
by	NULL
elutriation	NULL
(	NULL
counterflow	NULL
centrifugation	NULL
)	NULL
,	NULL
allowed	NULL
to	NULL
adhere	NULL
for	NULL
24	NULL
hr	NULL
to	NULL
plastic	NULL
culture	NULL
wells	NULL
precoated	NULL
with	NULL
AB+	NULL
human	NULL
serum	NULL
,	NULL
and	NULL
then	NULL
infected	NULL
in	NULL
vitro	NULL
with	NULL
HIV-15	NULL
,	NULL
.1	NULL
(	NULL
16	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
>	NULL
98	NULL
%	NULL
monocytes	NULL
and	NULL
were	NULL
>	NULL
98	NULL
%	NULL
viable	NULL
as	NULL
determined	NULL
by	NULL
morphology	NULL
,	NULL
a-naphthyl	NULL
esterase	NULL
staining	NULL
,	NULL
phagocytosis	NULL
of	NULL
latex	NULL
beads	NULL
,	NULL
and	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

A	NULL
4-	NULL
to	NULL
12-fold	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
,	NULL
compared	NULL
with	NULL
infected	NULL
cells	NULL
cultured	NULL
without	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
was	NULL
seen	NULL
at	NULL
concentrations	NULL
of	NULL
late	NULL
with	NULL
increased	NULL
HIV-1	NULL
replication	NULL
;	NULL
we	NULL
hypothesized	NULL
that	NULL
alterations	NULL
in	NULL
monocyte	NULL
CD4	NULL
expression	NULL
might	NULL
affect	NULL
HIV-1	NULL
replication	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
CD14	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD15	NULL
antigens	NULL
in	NULL
A3.5	NULL
cells	NULL
increased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
the	NULL
expression	NULL
of	NULL
CD4	NULL
and	NULL
HLA-DR	NULL
was	NULL
unchanged	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
CD14	NULL
increased	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
after	NULL
treatment	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
concentrations	NULL
ranging	NULL
from	NULL
24	NULL
pM	NULL
to	NULL
240	NULL
nM	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
modulation	NULL
of	NULL
CD4	NULL
expression	NULL
was	NULL
not	NULL
correlated	NULL
with	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
A3.5	NULL
cells	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
,	NULL
however	NULL
,	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
cell	NULL
surface	NULL
antigen	NULL
expression	NULL
in	NULL
different	NULL
monocyte	NULL
cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
can	NULL
vary	NULL
.	NULL

For	NULL
example	NULL
,	NULL
CD4	NULL
and	NULL
HLA-DR	NULL
expression	NULL
are	NULL
reduced	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
,	NULL
whereas	NULL
CD14	NULL
and	NULL
class	NULL
I	NULL
HLA	NULL
antigen	NULL
expression	NULL
are	NULL
unaffected	NULL
after	NULL
exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
17	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
intracellular	NULL
receptor	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
precursors	NULL
on	NULL
HIV-1	NULL
replication	NULL
.	NULL

These	NULL
precursors	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
either	NULL
bind	NULL
with	NULL
greatly	NULL
reduced	NULL
affinity	NULL
(	NULL
105	NULL
fold	NULL
)	NULL
to	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
intracellular	NULL
receptor	NULL
(	NULL
cholecalcif-erol	NULL
and	NULL
7-dehydrocholesterol	NULL
)	NULL
or	NULL
bind	NULL
with	NULL
somewhat	NULL
reduced	NULL
(	NULL
10+	NULL
to	NULL
affinity	NULL
[	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
;	NULL
refs	NULL
.	NULL

5	NULL
,	NULL
18	NULL
,	NULL
19	NULL
]	NULL
.	NULL

When	NULL
A3.5	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cholecalciferol	NULL
or	NULL
7-dehydrocholesterol	NULL
at	NULL
concentrations	NULL
ranging	NULL
up	NULL
to	NULL
26	NULL
nM	NULL
,	NULL
no	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
was	NULL
observed	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HIV-1	NULL
replication	NULL
was	NULL
enhanced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
.	NULL

The	NULL
potency	NULL
of	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
was	NULL
=200-	NULL
to	NULL
500-fold	NULL
less	NULL
than	NULL
that	NULL
of	NULL
Table	NULL
2	NULL
.	NULL

-	NULL
Cell	NULL
surface	NULL
marker	NULL
modulation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
in	NULL
A3.5	NULL
cells	NULL
%	NULL
positive	NULL
cells*	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
ranging	NULL
from	NULL
0.12	NULL
nM	NULL
to	NULL
1.0	NULL
nM	NULL
after	NULL
7	NULL
,	NULL
10	NULL
,	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
,	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
14	NULL
days	NULL
of	NULL
culture	NULL
.	NULL

Antigen	NULL
No	NULL
drug	NULL
24	NULL
nM	NULL
24	NULL
nM	NULL
2.4	NULL
uM	NULL
Enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
T	NULL
also	NULL
demonstrated	NULL
in	NULL
cocultures	NULL
of	NULL
PBMC	NULL
from	NULL
HIV-1	NULL
se-	NULL
Control	NULL
15	NULL
3.5	NULL
43	NULL
10.8	NULL
PR	NULL
f	NULL
.	NULL

CD4	NULL
93	NULL
(	NULL
73	NULL
)	NULL
94	NULL
(	NULL
59	NULL
)	NULL
98	NULL
(	NULL
71	NULL
)	NULL
97	NULL
(	NULL
63	NULL
)	NULL
ropositive	NULL
individuals	NULL
with	NULL
PBMC	NULL
from	NULL
seronegative	NULL
sub-	NULL
CDis	NULL
99	NULL
(	NULL
190	NULL
)	NULL
99	NULL
(	NULL
234	NULL
)	NULL
98	NULL
(	NULL
179	NULL
)	NULL
97	NULL
(	NULL
183	NULL
)	NULL
jects	NULL
.	NULL

HIV-1	NULL
replication	NULL
was	NULL
enhanced	NULL
in	NULL
five	NULL
of	NULL
seven	NULL
CD1lb	NULL
6.4	NULL
(	NULL
198	NULL
)	NULL
52	NULL
(	NULL
31	NULL
)	NULL
2.4	NULL
76	NULL
(	NULL
59	NULL
)	NULL
cultures	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
compared	NULL
HLA-DR	NULL
83	NULL
.	NULL

(	NULL
120	NULL
)	NULL
85	NULL
(	NULL
100	NULL
)	NULL
86	NULL
'	NULL
(	NULL
103	NULL
-	NULL
74	NULL
(	NULL
@	NULL
1	NULL
with	NULL
cocultures	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Polybrene	NULL
or	NULL
no	NULL
CDi4	NULL
drug	NULL
.	NULL

In	NULL
two	NULL
of	NULL
these	NULL
five	NULL
instances	NULL
,	NULL
HIV-1	NULL
was	NULL
recovered	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
but	NULL
not	NULL
when	NULL
cocultures	NULL
Egg	NULL
?	NULL

2	NULL
:	NULL
33	NULL
8:2	NULL
;	NULL
It	NULL
;	NULL
g	NULL
;	NULL
832	NULL
;	NULL
were	NULL
performed	NULL
with	NULL
Polybrene	NULL
alone	NULL
or	NULL
no	NULL
drug	NULL
.	NULL

In	NULL
the	NULL
other	NULL
three	NULL
cultures	NULL
,	NULL
HIV-1	NULL
was	NULL
detected	NULL
earlier	NULL
or	NULL
at	NULL
higher	NULL
titers	NULL
in	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
-treated	NULL
cells	NULL
than	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
cultures	NULL
containing	NULL
Polybrene	NULL
alone	NULL
or	NULL
no	NULL
drug	NULL
.	NULL

Polybrene	NULL
addition	NULL
did	NULL
not	NULL
increase	NULL
virus	NULL
yield	NULL
over	NULL
that	NULL
induced	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
alone	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
HIV-1	NULL
enhancement	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
initially	NULL
investigated	NULL
by	NULL
determining	NULL
if	NULL
alterations	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
surface	NULL
antigens	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
might	NULL
corre-	NULL
A3.5	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
ranging	NULL
from	NULL
24	NULL
pM	NULL
to	NULL
240	NULL
nM	NULL
(	NULL
only	NULL
24	NULL
nM	NULL
is	NULL
depicted	NULL
)	NULL
or	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
(	NULL
24	NULL
nM	NULL
and	NULL
2.4	NULL
uM	NULL
)	NULL
and	NULL
collected	NULL
at	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
hr	NULL
.	NULL

After	NULL
incubation	NULL
with	NULL
heat-aggregated	NULL
immunoglobulins	NULL
to	NULL
block	NULL
Fc	NULL
re-ceptors	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stained	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
for	NULL
CD4	NULL
,	NULL
HLA-DR	NULL
,	NULL
M1	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD14	NULL
antigens	NULL
and	NULL
counted	NULL
using	NULL
a	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
.	NULL

*Mean	NULL
fluorescence	NULL
is	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

*Fluorescein	NULL
isothiocyanate	NULL
conjugate	NULL
alone	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Skolnik	NULL
et	NULL
al	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
500	NULL
nM	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
enhanced	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
production	NULL
to	NULL
the	NULL
same	NULL
extent	NULL
as	NULL
0.96	NULL
nM	NULL
and	NULL
2.4	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
days	NULL
7	NULL
and	NULL
10	NULL
of	NULL
culture	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
mechanism	NULL
of	NULL
induction	NULL
of	NULL
replication	NULL
that	NULL
involves	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
.	NULL

Typical	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
demonstrated	NULL
previously	NULL
in	NULL
U937	NULL
cells	NULL
were	NULL
also	NULL
found	NULL
in	NULL
the	NULL
A3.5	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
;	NULL
method	NULL
as	NULL
in	NULL
ref	NULL
.	NULL

20	NULL
)	NULL
.	NULL

DISCUSSION	NULL
These	NULL
studies	NULL
demonstrate	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
enhances	NULL
HIV-1	NULL
replication	NULL
in	NULL
monocyte	NULL
cell	NULL
lines	NULL
,	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
,	NULL
and	NULL
cocultures	NULL
of	NULL
PBMC	NULL
from	NULL
HIV-1	NULL
seropositive	NULL
individuals	NULL
to	NULL
a	NULL
degree	NULL
similar	NULL
to	NULL
or	NULL
greater	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
most	NULL
potent	NULL
regulator	NULL
of	NULL
HIV-1	NULL
expression	NULL
(	NULL
the	NULL
HIV-1	NULL
tat	NULL
protein	NULL
)	NULL
described	NULL
to	NULL
date	NULL
.	NULL

We	NULL
consistently	NULL
observed	NULL
enhancement	NULL
at	NULL
physiologic	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
~0.12	NULL
nM	NULL
)	NULL
in	NULL
the	NULL
experiments	NULL
with	NULL
the	NULL
A3.5	NULL
cell	NULL
line	NULL
and	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
separated	NULL
by	NULL
elutriation	NULL
{	NULL
e.g	NULL
.	NULL

,	NULL
Fig	NULL
.	NULL

2B	NULL
[	NULL
normalized	NULL
to	NULL
control	NULL
values	NULL
without	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
]	NULL
}	NULL
.	NULL

This	NULL
enhancement	NULL
occurred	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

It	NULL
should	NULL
be	NULL
mentioned	NULL
that	NULL
local	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
may	NULL
be	NULL
higher	NULL
than	NULL
circulating	NULL
levels	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
UV	NULL
irradiation	NULL
can	NULL
transiently	NULL
increase	NULL
circulating	NULL
levels	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
normal	NULL
volunteers	NULL
(	NULL
~25	NULL
%	NULL
)	NULL
and	NULL
dramatically	NULL
increase	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
levels	NULL
in	NULL
vitamin	NULL
D-deficient	NULL
patients	NULL
(	NULL
~300	NULL
%	NULL
;	NULL
ref	NULL
.	NULL

21	NULL
)	NULL
.	NULL

Vitamin	NULL
supplements	NULL
increase	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
levels	NULL
above	NULL
the	NULL
physiologic	NULL
level	NULL
;	NULL
our	NULL
in	NULL
vitro	NULL
data	NULL
indicate	NULL
that	NULL
this	NULL
might	NULL
be	NULL
an	NULL
undesirable	NULL
effect	NULL
.	NULL

After	NULL
performing	NULL
dose-response	NULL
experiments	NULL
in	NULL
each	NULL
cell	NULL
type	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
study	NULL
higher	NULL
doses	NULL
in	NULL
subsequent	NULL
experiments	NULL
to	NULL
more	NULL
easily	NULL
measure	NULL
differences	NULL
in	NULL
the	NULL
effects	NULL
on	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
cellular	NULL
and	NULL
molecular	NULL
events	NULL
underlying	NULL
the	NULL
immuno-modulatory	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
elu-cidated	NULL
.	NULL

One	NULL
of	NULL
the	NULL
major	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
the	NULL
induction	NULL
of	NULL
changes	NULL
in	NULL
calcium	NULL
flux	NULL
across	NULL
cell	NULL
membranes	NULL
;	NULL
this	NULL
may	NULL
occur	NULL
after	NULL
binding	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
its	NULL
cytosolic	NULL
receptor	NULL
or	NULL
more	NULL
rapidly	NULL
,	NULL
without	NULL
transcriptional	NULL
effects	NULL
,	NULL
after	NULL
interaction	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
with	NULL
the	NULL
cell	NULL
membrane	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
HIV	NULL
infection	NULL
of	NULL
cells	NULL
,	NULL
or	NULL
the	NULL
binding	NULL
of	NULL
HIV-1	NULL
gp120	NULL
to	NULL
CD4	NULL
,	NULL
also	NULL
results	NULL
in	NULL
increased	NULL
levels	NULL
of	NULL
intracellular	NULL
calcium	NULL
and	NULL
inositol	NULL
triphos-phate	NULL
,	NULL
which	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
modulation	NULL
of	NULL
HIV	NULL
replication	NULL
or	NULL
pathogenic	NULL
effects	NULL
of	NULL
HIV	NULL
(	NULL
24	NULL
)	NULL
.	NULL

HIV-1	NULL
gp120	NULL
induces	NULL
an	NULL
increase	NULL
in	NULL
concentration	NULL
of	NULL
intracellular	NULL
free	NULL
calcium	NULL
that	NULL
is	NULL
associated	NULL
with	NULL
toxicity	NULL
to	NULL
rodent	NULL
retinal	NULL
ganglion	NULL
cells	NULL
and	NULL
hippocampal	NULL
neurons	NULL
;	NULL
these	NULL
effects	NULL
are	NULL
abrogated	NULL
by	NULL
the	NULL
calcium	NULL
channel	NULL
blocker	NULL
nimodipine	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Diphenylhydantoin	NULL
inhibits	NULL
the	NULL
HIV	NULL
-induced	NULL
increase	NULL
in	NULL
concentration	NULL
of	NULL
intracellular	NULL
calcium	NULL
and	NULL
potentiates	NULL
the	NULL
anti-retroviral	NULL
activity	NULL
of	NULL
zidovudine	NULL
(	NULL
AZT	NULL
)	NULL
in	NULL
some	NULL
cell	NULL
lines	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Steroid	NULL
hormones	NULL
influence	NULL
transactivation	NULL
of	NULL
promoter	NULL
regions	NULL
in	NULL
other	NULL
retroviral	NULL
systems	NULL
.	NULL

The	NULL
mouse	NULL
mammary	NULL
tumor	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
contains	NULL
a	NULL
cis-acting	NULL
target	NULL
[	NULL
glucocorticoid	NULL
response	NULL
element	NULL
(	NULL
GRE	NULL
)	NULL
]	NULL
for	NULL
the	NULL
glu-cocorticoid-receptor	NULL
complex	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

This	NULL
DNA-protein/	NULL
receptor	NULL
interaction	NULL
increases	NULL
transcription	NULL
from	NULL
linked	NULL
initiation	NULL
sites	NULL
relatively	NULL
independently	NULL
of	NULL
the	NULL
orientation	NULL
of	NULL
the	NULL
GRE	NULL
or	NULL
its	NULL
distance	NULL
from	NULL
heterologous	NULL
promoters	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Cellular	NULL
transcription	NULL
factors	NULL
(	NULL
the	NULL
mouse	NULL
homolog	NULL
of	NULL
NF-1	NULL
,	NULL
F-i	NULL
)	NULL
may	NULL
also	NULL
be	NULL
important	NULL
in	NULL
this	NULL
interaction	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

NF-1	NULL
may	NULL
influence	NULL
the	NULL
effect	NULL
of	NULL
various	NULL
steroids	NULL
on	NULL
the	NULL
relevant	NULL
hormone	NULL
response	NULL
element	NULL
(	NULL
HRE	NULL
)	NULL
in	NULL
this	NULL
system	NULL
by	NULL
binding	NULL
to	NULL
regions	NULL
outside	NULL
of	NULL
HRE	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Steroid	NULL
hormones	NULL
may	NULL
also	NULL
affect	NULL
HIV-1	NULL
replication	NULL
.	NULL

Tamoxifen	NULL
can	NULL
block	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
-induced	NULL
HIV-1	NULL
replication	NULL
in	NULL
the	NULL
U1	NULL
clone	NULL
,	NULL
and	NULL
tamoxifen	NULL
and	NULL
dexamethasone	NULL
block	NULL
PMA	NULL
enhancement	NULL
of	NULL
expression	NULL
of	NULL
a	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
6635	NULL
HIV-LTR	NULL
chloramphenicol	NULL
acetylitransferase	NULL
construct	NULL
co-transfected	NULL
with	NULL
the	NULL
rat	NULL
gene	NULL
in	NULL
cells	NULL
of	NULL
monocyte	NULL
and	NULL
CD4*	NULL
lineage	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Some	NULL
investigators	NULL
have	NULL
reported	NULL
inhibitory	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
HIV-1	NULL
replication	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Others	NULL
have	NULL
shown	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
facilitates	NULL
HIV-1	NULL
infection	NULL
and	NULL
replication	NULL
in	NULL
HL-60	NULL
and	NULL
chronically	NULL
infected	NULL
U937	NULL
cells	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Our	NULL
investigations	NULL
demonstrate	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
acutely	NULL
infected	NULL
monocyte	NULL
cell	NULL
lines	NULL
(	NULL
A3.5	NULL
and	NULL
U937	NULL
cells	NULL
)	NULL
and	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
;	NULL
however	NULL
,	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
behaves	NULL
quite	NULL
differently	NULL
than	NULL
its	NULL
``	NULL
parental	NULL
``	NULL
U937	NULL
cell	NULL
line	NULL
and	NULL
the	NULL
A3.5	NULL
cell	NULL
line	NULL
in	NULL
experiments	NULL
involving	NULL
induction	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Monocytoid	NULL
cell	NULL
lines	NULL
often	NULL
differ	NULL
from	NULL
each	NULL
other	NULL
in	NULL
several	NULL
ways	NULL
,	NULL
including	NULL
cytokine	NULL
production	NULL
,	NULL
the	NULL
detailed	NULL
kinetics	NULL
of	NULL
HIV-1	NULL
replication	NULL
,	NULL
cell	NULL
surface	NULL
marker	NULL
modulation	NULL
,	NULL
and	NULL
kinetics	NULL
of	NULL
cellular	NULL
proliferation	NULL
.	NULL

Our	NULL
experiments	NULL
showing	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
may	NULL
be	NULL
particularly	NULL
important	NULL
in	NULL
this	NULL
regard	NULL
as	NULL
they	NULL
suggest	NULL
that	NULL
models	NULL
showing	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
may	NULL
more	NULL
closely	NULL
parallel	NULL
the	NULL
in	NULL
vivo	NULL
situation	NULL
.	NULL

Our	NULL
investigations	NULL
also	NULL
suggest	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
intracellular	NULL
receptor	NULL
in	NULL
these	NULL
effects	NULL
.	NULL

Intracellular	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
are	NULL
found	NULL
in	NULL
many	NULL
tissues	NULL
,	NULL
including	NULL
brain	NULL
,	NULL
thymus	NULL
,	NULL
bone	NULL
marrow	NULL
,	NULL
intestine	NULL
,	NULL
colon	NULL
,	NULL
kidney	NULL
,	NULL
bone	NULL
,	NULL
muscle	NULL
,	NULL
and	NULL
lung	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Monocytes	NULL
and	NULL
activated	NULL
,	NULL
but	NULL
not	NULL
resting	NULL
,	NULL
T	NULL
cells	NULL
have	NULL
this	NULL
receptor	NULL
.	NULL

Several	NULL
possible	NULL
explanations	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
observed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
are	NULL
possible	NULL
.	NULL

The	NULL
steroid	NULL
hormone	NULL
and	NULL
its	NULL
intracellular	NULL
receptor	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
relevant	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
genome	NULL
and	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
alter	NULL
intracellular	NULL
calcium	NULL
levels	NULL
or	NULL
other	NULL
relevant	NULL
cellular	NULL
correlates	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
activity	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
recep-tor-ligand	NULL
complexes	NULL
could	NULL
bind	NULL
to	NULL
regulatory	NULL
regions	NULL
within	NULL
the	NULL
HIV-LTR	NULL
that	NULL
share	NULL
sequence	NULL
homology	NULL
to	NULL
the	NULL
relevant	NULL
steroid	NULL
hormone	NULL
response	NULL
elements	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
known	NULL
that	NULL
steroid	NULL
receptor	NULL
binding	NULL
sites	NULL
are	NULL
often	NULL
found	NULL
clustered	NULL
with	NULL
binding	NULL
sites	NULL
for	NULL
other	NULL
cellular	NULL
transcription	NULL
factors	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
NF-kB	NULL
and	NULL
Sp-1	NULL
(	NULL
39	NULL
)	NULL
]	NULL
;	NULL
these	NULL
may	NULL
act	NULL
synergistically	NULL
to	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
or	NULL
steroid	NULL
hormone	NULL
effects	NULL
.	NULL

UV	NULL
light	NULL
can	NULL
induce	NULL
HIV-1	NULL
expression	NULL
,	NULL
perhaps	NULL
through	NULL
a	NULL
mechanism	NULL
involving	NULL
heat-shock	NULL
proteins	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

UV	NULL
light	NULL
activation	NULL
of	NULL
a	NULL
HIV-LTR	NULL
construct	NULL
in	NULL
transgenic	NULL
mice	NULL
has	NULL
been	NULL
demonstrated	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Enhancement	NULL
of	NULL
HIV-1	NULL
replication	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
may	NULL
be	NULL
relevant	NULL
in	NULL
this	NULL
in	NULL
vivo	NULL
system	NULL
,	NULL
since	NULL
UV	NULL
light	NULL
is	NULL
known	NULL
to	NULL
promote	NULL
25-hydroxylation	NULL
of	NULL
cholecalciferol	NULL
in	NULL
skin	NULL
.	NULL

Our	NULL
studies	NULL
may	NULL
have	NULL
important	NULL
biological	NULL
and	NULL
clinical	NULL
implications	NULL
.	NULL

We	NULL
have	NULL
described	NULL
a	NULL
monocyte	NULL
cell	NULL
line	NULL
that	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
HIV-1	NULL
and	NULL
provides	NULL
a	NULL
model	NULL
to	NULL
study	NULL
factors	NULL
that	NULL
influence	NULL
HIV-1	NULL
replication	NULL
during	NULL
acute	NULL
infection	NULL
.	NULL

Studies	NULL
with	NULL
chronically	NULL
infected	NULL
cells	NULL
should	NULL
also	NULL
be	NULL
possible	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
cell	NULL
cultures	NULL
should	NULL
optimize	NULL
recovery	NULL
of	NULL
HIV-1	NULL
and	NULL
aid	NULL
in	NULL
the	NULL
diagnosis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
compounds	NULL
that	NULL
generate	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
cholecalciferol	NULL
and	NULL
ergocalciferol	NULL
)	NULL
might	NULL
have	NULL
adverse	NULL
effects	NULL
in	NULL
individuals	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

These	NULL
compounds	NULL
are	NULL
used	NULL
to	NULL
treat	NULL
several	NULL
diseases	NULL
,	NULL
and	NULL
some	NULL
are	NULL
readily	NULL
available	NULL
in	NULL
health-food	NULL
stores	NULL
as	NULL
vitamin	NULL
supplements	NULL
.	NULL

Finally	NULL
,	NULL
specific	NULL
antagonists	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
might	NULL
inhibit	NULL
virus	NULL
replication	NULL
.	NULL

Such	NULL
compounds	NULL
could	NULL
provide	NULL
novel	NULL
therapeutic	NULL
agents	NULL
for	NULL
HIV-1-infected	NULL
individuals	NULL
.	NULL

We	NULL
thank	NULL
S.	NULL
Wolff	NULL
for	NULL
his	NULL
advice	NULL
and	NULL
encouragement	NULL
and	NULL
M.	NULL
Pechet	NULL
,	NULL
L.	NULL
Avioli	NULL
,	NULL
B.	NULL
Ardman	NULL
,	NULL
J.	NULL
Lieberman	NULL
,	NULL
and	NULL
D.	NULL
Schenkein	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
suggestions	NULL
.	NULL

The	NULL
following	NULL
reagents	NULL
were	NULL
obtained	NULL
through	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Pro-gram	NULL
,	NULL
Division	NULL
of	NULL
AIDS	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
:	NULL
U1	NULL
cells	NULL
(	NULL
contributor	NULL
,	NULL
Dr.	NULL
Thomas	NULL
Folks	NULL
)	NULL
and	NULL
(	NULL
contributors	NULL
,	NULL
Drs	NULL
.	NULL

Suzanne	NULL
Gartner	NULL
,	NULL
Mikulas	NULL
Popovic	NULL
,	NULL
and	NULL
Robert	NULL
Gallo	NULL
)	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
6636	NULL
Medical	NULL
Sciences	NULL
:	NULL
Skolnik	NULL
et	NULL
al	NULL
.	NULL

grants	NULL
from	NULL
the	NULL
Life	NULL
and	NULL
Health	NULL
Insurance	NULL
Medical	NULL
Research	NULL
Fund	NULL
and	NULL
the	NULL
Carter-Wallace	NULL
Foundation	NULL
(	NULL
P.R.S	NULL
.	NULL
)	NULL

;	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Deutscher	NULL
Akademischer	NULL
Austauschdienst	NULL
Sondeprogramm	NULL
Rheu-matologie	NULL
(	NULL
B.J	NULL
.	NULL
)	NULL

;	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA-12464	NULL
and	NULL
CA-35020	NULL
(	NULL
M.S.H	NULL
.	NULL
)	NULL

and	NULL
AR-03564	NULL
(	NULL
S.M.K	NULL
.	NULL
)	NULL

.	NULL

1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Orenstein	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Baca	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Weiser	NULL
,	NULL
B.	NULL
,	NULL
Burger	NULL
,	NULL
H.	NULL
,	NULL
Kalter	NULL
,	NULL
D.	NULL
C.	NULL
&	NULL
Meltzer	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
AIDS	NULL
3	NULL
,	NULL
475-495	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
Leung	NULL
,	NULL
K.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
&	NULL
Nabel	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
339	NULL
,	NULL
70-73	NULL
.	NULL

Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
453-475	NULL
.	NULL

Minghetti	NULL
,	NULL
P.	NULL
P.	NULL
&	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

2	NULL
,	NULL
3043-3053	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
9	NULL
,	NULL
54-58	NULL
.	NULL

Kazazi	NULL
,	NULL
F.	NULL
,	NULL
Mathijs	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Foley	NULL
,	NULL
P.	NULL
&	NULL
Cunningham	NULL
,	NULL
A.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
2661-2672	NULL
.	NULL

Firestein	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Reifler	NULL
,	NULL
D.	NULL
,	NULL
Richman	NULL
,	NULL
D.	NULL
&	NULL
Gruber	NULL
,	NULL
H.	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

113	NULL
,	NULL
63-69	NULL
.	NULL

Zagury	NULL
,	NULL
D.	NULL
,	NULL
Bernard	NULL
,	NULL
J.	NULL
,	NULL
Leonard	NULL
,	NULL
R.	NULL
,	NULL
Cheynier	NULL
,	NULL
R.	NULL
,	NULL
Feldman	NULL
,	NULL
M.	NULL
,	NULL
Sarin	NULL
,	NULL
P.	NULL
S.	NULL
&	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1986	NULL
)	NULL
Science	NULL
231	NULL
,	NULL
850-853	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Luciw	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Peterlin	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84	NULL
,	NULL
6845-6849	NULL
.	NULL

Wahl	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Katona	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
Wilder	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Winter	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Haraoui	NULL
,	NULL
B.	NULL
,	NULL
Scher	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Wahl	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1984	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

85	NULL
,	NULL
373-383	NULL
.	NULL

Skolnik	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Kosloff	NULL
,	NULL
B.	NULL
R.	NULL
&	NULL
Hirsch	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

157	NULL
,	NULL
508-514	NULL
.	NULL

Skolnik	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Kosloff	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Bechtel	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Huskins	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Flynn	NULL
,	NULL
T.	NULL
,	NULL
Karthas	NULL
,	NULL
N.	NULL
,	NULL
Mcintosh	NULL
,	NULL
K.	NULL
&	NULL
Hirsch	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

160	NULL
,	NULL
1056-1060	NULL
.	NULL

Moscicki	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Amento	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Krane	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Kurnick	NULL
,	NULL
J.	NULL
T.	NULL
&	NULL
Colvin	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

131	NULL
,	NULL
743-748	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Justement	NULL
,	NULL
J.	NULL
,	NULL
Kinter	NULL
,	NULL
A.	NULL
,	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
238	NULL
,	NULL
800-802	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Justement	NULL
,	NULL
J.	NULL
,	NULL
Kinter	NULL
,	NULL
A.	NULL
,	NULL
Schnittman	NULL
,	NULL
S.	NULL
,	NULL
Orenstein	NULL
,	NULL
J.	NULL
,	NULL
Poli	NULL
,	NULL
G.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
1117-1122	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
Markovits	NULL
,	NULL
P.	NULL
,	NULL
Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kaplan	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
&	NULL
Popovic	NULL
,	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Science	NULL
233	NULL
,	NULL
215-219	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
Waugh	NULL
,	NULL
M.	NULL
&	NULL
Graziano	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
76	NULL
,	NULL
189-197	NULL
.	NULL

Eisman	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
(	NULL
1977	NULL
)	NULL
Steroids	NULL
30	NULL
,	NULL
245-257	NULL
.	NULL

Brumbaugh	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Haussler	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Bursac	NULL
,	NULL
K.	NULL
M.	NULL
&	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1974	NULL
)	NULL
Biochemistry	NULL
13	NULL
,	NULL
4091-4097	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Amento	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Clemens	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Holick	NULL
,	NULL
M.	NULL
F.	NULL
21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
&	NULL
Krane	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

57	NULL
,	NULL
1308-1310	NULL
.	NULL

Adams	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Clemens	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Parrish	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Hollick	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
1982	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

306	NULL
,	NULL
722-725	NULL
.	NULL

Polla	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Bonventre	NULL
,	NULL
J.	NULL
V.	NULL
&	NULL
Krane	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

107	NULL
,	NULL
373-380	NULL
.	NULL

Desai	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Appel	NULL
,	NULL
M.	NULL
C.	NULL
&	NULL
Baran	NULL
,	NULL
D.	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

Bone	NULL
Miner	NULL
.	NULL

Res	NULL
.	NULL

1	NULL
,	NULL
497-501	NULL
.	NULL

Kornfeld	NULL
,	NULL
H.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Pyle	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Berman	NULL
,	NULL
J.	NULL
S.	NULL
&	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
335	NULL
,	NULL
445-448	NULL
.	NULL

Dreyer	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
Kaiser	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Offermann	NULL
,	NULL
J.	NULL
T.	NULL
&	NULL
Lipton	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
364-367	NULL
.	NULL

Cloyd	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Lynn	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Ramsey	NULL
,	NULL
K.	NULL
&	NULL
Baron	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Virology	NULL
173	NULL
,	NULL
581-590	NULL
.	NULL

Chandler	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
Maler	NULL
,	NULL
B	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
(	NULL
1983	NULL
)	NULL
Cell	NULL
33	NULL
,	NULL
489-499	NULL
.	NULL

Ringold	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Bishop	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Varmus	NULL
,	NULL
H.	NULL
E.	NULL
(	NULL
1977	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
74	NULL
,	NULL
2879-2883	NULL
.	NULL

Cordingley	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Riegel	NULL
,	NULL
A.	NULL
T.	NULL
&	NULL
Hager	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
48	NULL
,	NULL
261-270	NULL
.	NULL

Scolnick	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

&	NULL
Parks	NULL
,	NULL
W.	NULL
P.	NULL
(	NULL
1976	NULL
)	NULL
Virology	NULL
69	NULL
,	NULL
148-156	NULL
.	NULL

Cato	NULL
,	NULL
A.	NULL
C.	NULL
B.	NULL
,	NULL
Skroch	NULL
,	NULL
P.	NULL
,	NULL
Weinmann	NULL
,	NULL
J.	NULL
,	NULL
Butkeraitis	NULL
,	NULL
P.	NULL
&	NULL
Ponta	NULL
,	NULL
H.	NULL
(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
1403-1410	NULL
.	NULL

Laurence	NULL
,	NULL
J.	NULL
,	NULL
Cooke	NULL
,	NULL
H.	NULL
&	NULL
Sikder	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
75	NULL
,	NULL
696-703	NULL
.	NULL

Laurence	NULL
,	NULL
J.	NULL
,	NULL
Sellers	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

&	NULL
Sikder	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Blood	NULL
74	NULL
,	NULL
291-297	NULL
.	NULL

Pauza	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Galindo	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Richman	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

62	NULL
,	NULL
3558-3564	NULL
.	NULL

Kitano	NULL
,	NULL
K.	NULL
,	NULL
Baldwin	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Raines	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Golde	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
76	NULL
,	NULL
1980-1988	NULL
.	NULL

Locardi	NULL
,	NULL
C.	NULL
,	NULL
Petrini	NULL
,	NULL
C.	NULL
,	NULL
Boccoli	NULL
,	NULL
G.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Dieffenbach	NULL
,	NULL
C.	NULL
,	NULL
Butto	NULL
,	NULL
S.	NULL
&	NULL
Belardelli	NULL
,	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

64	NULL
,	NULL
5874-5882	NULL
.	NULL

Kerner	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Scott	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

&	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
4455-4459	NULL
.	NULL

Morrison	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Shine	NULL
,	NULL
J.	NULL
,	NULL
Fragonas	NULL
,	NULL
J.-C.	NULL
,	NULL
Verkest	NULL
,	NULL
V.	NULL
,	NULL
McMeneny	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Eisman	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1158-1161	NULL
.	NULL

Schiile	NULL
,	NULL
R.	NULL
,	NULL
Mulier	NULL
,	NULL
M.	NULL
,	NULL
Kaltschmidt	NULL
,	NULL
C.	NULL
&	NULL
Renkawitz	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
242	NULL
,	NULL
1418-1420	NULL
.	NULL

Valerie	NULL
,	NULL
K.	NULL
,	NULL
Delers	NULL
,	NULL
A.	NULL
,	NULL
Bruck	NULL
,	NULL
C.	NULL
,	NULL
Thiriart	NULL
,	NULL
C.	NULL
,	NULL
Rosenberg	NULL
,	NULL
H.	NULL
,	NULL
Debouck	NULL
,	NULL
C.	NULL
&	NULL
Rosenberg	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
333	NULL
,	NULL
78-81	NULL
.	NULL

Stanley	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
5	NULL
,	NULL
375-384	NULL
.	NULL

Cavard	NULL
,	NULL
C.	NULL
,	NULL
Zider	NULL
,	NULL
A.	NULL
,	NULL
Vernet	NULL
,	NULL
M.	NULL
,	NULL
Bennoun	NULL
,	NULL
M.	NULL
,	NULL
Saragosti	NULL
,	NULL
S.	NULL
,	NULL
Grimber	NULL
,	NULL
G.	NULL
&	NULL
Briand	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

86	NULL
,	NULL
1369-1374	NULL
.	NULL

